Floatz logo

gsk1120212

Metastatic Solid Tumor

Turning Point Therapeutics, Inc.Phase 1/2Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
65/ 100

Competitive context

131 Active assets in the Metastatic Solid Tumor cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
InSilico Medicine Hong Kong Limited
Phase 2CCC
Pembrolizumab
InSilico Medicine Hong Kong Limited
Phase 2CCC
Epirubicin
InSilico Medicine Hong Kong Limited
Phase 2CCC
Nivolumab
Lantern Pharma Inc.
Phase 2CCC
Trastuzumab Emtansine
M.D. Anderson Cancer Center
Phase 2CCC

View all 50 →

Same molecule, other indications

gsk1120212 is also rated in:

anaplastic pleomorphic xanthoastrocytomaDormant
BB
Indicative ·
69 / 100
View asset →
Glioma, High GradeDormant
BB
Indicative ·
69 / 100
View asset →
anaplastic oligodendrogliomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →